Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Vertex currently generates most of its revenue from its drugs that treat cystic fibrosis (CF), a rare disease that causes ...

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

They could both outperform the market over the medium term, but one appears to have a clear edge.
Zacks Investment Research on MSN

Investors heavily search Vertex Pharmaceuticals Incorporated (VRTX): Here is what you need to know

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics ...

Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution

Vertex Pharmaceuticals Incorporated (VRTX) remains a 'Hold' as upside is constrained by valuation and execution risks outside ...

Vertex wins Overweight at Morgan Stanley as coverage resumes after Crinetics buyout

Vertex Pharmaceuticals (VRTX) stock rises as Morgan Stanley resumes coverage with an Overweight recommendation and a $665 ...

Vertex makes some big people moves, completes its largest acquisition

Chief executive Reshma Kewalramani is expanding her top leadership team to accommodate the Boston biotech’s growth.
STAT

Inside Vertex’s decades-long quest to develop a new class of non-opioid painkillers

SAN DIEGO — For decades, the biotech industry has tried — and repeatedly failed — to develop new and effective painkillers without the addictive potential of opioids. But there’s reason to think that ...